Table 1.

Genentech's approved antibodies in 4D5 framework

Ab name	DrugBank accession	Target(s)	Indication^a	PDB ID
Atezolizumab	DB11595	PD-L1	Non-small-cell lung cancer, small-cell lung cancer, hepatocellular carcinoma, melanoma, alveolar soft part sarcoma	5X8L
Bevacizumab	DB00112	VEGF	MCC (metastatic colorectal cancer), nonsquamous non-small-cell lung cancer, metastatic breast cancer glioblastoma, metastatic colorectal cancer, nonsquamous non-small-cell lung cancer	6BFT
Efalizumab^b	DB00095	LFA-1	Adult patients with moderate to severe chronic plaque psoriasis	3EOA
Emicizumab	DB13923	Factor IX/X	Prophylaxis to prevent/reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia A	NA
Mosunetuzumab^c (CD20 arm)	DB15434	CD20/CD3	Adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies	NA
Ocrelizumab	DB11988	CD20	Adult patients with relapsing or primary progressive forms of multiple sclerosis	NA
Omalizumab	DB00043	IgE	Moderate to severe persistent allergic asthma that is not controlled by inhaled steroids	5HYS
Pertuzumab	DB06366	HER2	HER2-positive metastatic breast cancer	1S78
Ranibizumab	DB01270	VEGF	Neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization	NA
Trastuzumab	DB	HER2	HER2-positive metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma	1N8Z

(PDB) Protein Data Bank.
^aIndications obtained from DrugBank entries.
^bVoluntarily withdrawn from the market after three confirmed and one suspected case of progressive multifocal leukoencephalopathy (PML) were spontaneously reported.
^cGranted accelerated approval on December 22, 2022.